NSP 513

Drug Profile

NSP 513

Latest Information Update: 12 Feb 2008

Price : $50

At a glance

  • Originator Nippon Soda
  • Developer Banyu; Nippon Soda
  • Class Antithrombotics; Pyridazines
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 12 Feb 2008 Discontinued - Preclinical for Thrombosis in Japan (unspecified route)
  • 31 Mar 2004 Banyu Pharmaceutical has become a wholly owned subsidiary of Merck & Co
  • 16 May 2000 Preclinical development for Thrombosis in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top